4basebio PLC announced it has received a grant from the Bill & Melinda Gates Foundation to advance the development program of thermostable nucleic acid based vaccines. The development program aims to build on preclinical data demonstrating the improved stability offered by the Hermes? platform, the superior immune responses achieved with 4basebio's synthetic DNA products and high-quality mRNA produced from 4basebio opDNA?

products. The successful demonstration of the Hermes? platform and 4basebio synthetic nucleic acid payloads in infectious disease vaccines has the potential to enhance the global availability of such innovative medicines.